Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)
Open Access
- 29 November 2022
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 206, 107065
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme United Kingdom (MK-5475)
This publication has 8 references indexed in Scilit:
- Risk stratification and medical therapy of pulmonary arterial hypertensionEuropean Respiratory Journal, 2019
- Haemodynamic definitions and updated clinical classification of pulmonary hypertensionEuropean Respiratory Journal, 2019
- Pulmonary Arterial Hypertension: Combination Therapy in PracticeAmerican Journal of Cardiovascular Drugs, 2018
- Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertensionInternational Journal of Chronic Obstructive Pulmonary Disease, 2016
- Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)Circulation, 2015
- Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equationEuropean Respiratory Journal, 2009
- First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionEuropean Respiratory Journal, 2009
- THE APPLICATION OF THE FICK PRINCIPLE TO THE MEASUREMENT OF PULMONARY BLOOD FLOWProceedings of the National Academy of Sciences, 1958